Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Cardiometabolic and MASH/NASH Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for STK25 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | STK25 Active Kinase Domain / Full Length Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Suitable for enzymatic assays. |
View STK25 Products |
| Gene Delivery | STK25 Promise-ORF / Lentivirus Full-length ORF for stable hepatocyte cell line construction to evaluate lipid accumulation. |
View STK25 Products |
| Benchmark Ab | Anti-STK25 Recombinant Antibody Recombinant positive control for Western Blot, ELISA, and IP validation. |
View STK25 Products |
| Validator | STK25 siRNA Set For target knockdown verification in metabolic assay models. |
View STK25 Products |
| Related Target A | STK24 (MST3) Subfamily homolog. Critical counter-screening target to evaluate small molecule kinase selectivity. |
View STK24 Products |
| Related Target B | AMPK Downstream metabolic master regulator. Crucial for assessing metabolic pathway restoration. |
View AMPK Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity profiling against STE20 subfamily kinases | Homolog panel proteins (STK24, STK26) strictly verified by mass spectrometry and high purity (>95%) for clean IC50 curves. |
| In vitro kinase assay reproducibility | Sequence-verified catalytic domains with optimized phosphorylation status, ensuring consistent baseline activity. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives in Phenotypic Screens | Validated siRNA included for specificity checks |
Live STK25 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for STK25 therapeutics is intensifying, with major players shifting focus from traditional systemic metabolic regulators to tissue-specific small molecules and targeted genetic medicines. As first-generation therapies reach preclinical and early clinical milestones, the next wave of R&D is targeting selective STK25 inhibition to treat Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) and Type 2 Diabetes without inducing off-target systemic toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule | AstraZeneca, Academic Institutions | MASH / NASH, Type 2 Diabetes | Selectivity Assay (Need high-purity STK24/STK25/STK26 proteins to avoid off-target GCKIII toxicity) |
| ASO / siRNA | Ionis Pharmaceuticals, Alnylam | Severe Hepatic Steatosis, Obesity | Knockdown Validation (Need high-titer Lentivirus for stable cell lines and validated siRNA sets) |
| Gene Therapy / CRISPR | Biotech Startups | Genetic Metabolic Disorders | Expression Verification (Need sequence-verified ORF constructs and high-affinity detection antibodies) |